Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter was issued to Stanley Specialty Pharmacy Compounding and Wellness Center on July 24, 2018. The letter addresses compliance issues at a specialty pharmacy compounding operation, though the specific nature of the violations cannot be determined from the available metadata. Without access to the full letter text or detailed subject information, the precise regulatory concerns and scope of non-compliance remain unclear, though they likely relate to pharmacy compounding practices or product quality standards.